Skip to main content
Terug
Watch Compare

BioScience Health Innovations, Inc.

Datakwaliteit: 100%
BHIC
OTC Technology Cloud & Data Services
€ 2,15
▼ € 0,06 (-2,71%)
Marktkapitalisatie: 24,44 M
Prijs
€ 2,15
Marktkapitalisatie
24,44 M
Dagbereik
€ 2,15 — € 2,15
52-Weeksbereik
€ 0,52 — € 52,00
Volume
300
Openen € 2,15
50D / 200D Gem.
€ 3,48
38,17% below
50D / 200D Gem.
€ 7,23
70,26% below

Quick Summary

Belangrijkste Punten

Earnings grew 638,03% over the past year
ROE of 37,43% indicates high profitability
Generating 172.178,0 in free cash flow
P/E of 38,06 — premium valuation
ROIC of 27,55% — excellent capital efficiency

Groei

Revenue Growth (5Y)
N/A
Revenue (1Y)208,34%
Earnings (1Y)638,03%
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
37,43%
Boven sectorgemiddelde (1,81%)
ROIC27,55%
Net Margin11,29%
Op. Margin12,64%

Veiligheid

Debt / Equity
N/A
Current RatioN/A
Interest CoverageN/A

Waardering

PE (TTM)
38,06
Boven sectorgemiddelde (-0,15)
P/B Ratio14,28
EV/EBITDA32,40
Dividend YieldN/A

Koershistorie

Financiële Trends

Sectorvergelijking

vs Technology sector mediaan (1058 peers)
Metriek Aandeel Sector Mediaan
P/E 38,1 -0,1
P/B 14,3 3,0
ROE % 37,4 1,8
Net Margin % 11,3 -0,5
Rev Growth 5Y % — 7,2
D/E — 0,4

All Fundamental Metrics
Growth
Revenue Growth (1Y) 208,34% Revenue Growth (3Y) 208,53%
Earnings Growth (1Y) 638,03% Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 5,69 M Net Income (TTM) 642.090,0
ROE 37,43% ROA 31,14%
Gross Margin 56,97% Operating Margin 12,64%
Net Margin 11,29% Free Cash Flow (TTM) 172.178,0
ROIC 27,55% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio N/A
Interest Coverage N/A Asset Turnover 2,76
Working Capital N/A Tangible Book Value 1,64 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio 38,06 Forward P/E N/A
P/B Ratio 14,28 P/S Ratio 4,30
PEG Ratio N/A Forward PEG N/A
EV/EBITDA 32,40 Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield 0,70%
Market Cap 24,44 M Enterprise Value 23,30 M
Per Share
EPS (Diluted TTM) 0,06 Revenue / Share 0,50
FCF / Share 0,02 OCF / Share 0,02
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 26,82%
SBC-Adj. FCF N/A Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 5,69 M 1,84 M 597.595,0 0,0 0,0
Net Income 642.090,0 87.000,0 -251.500,0 -83.208,0 -25.610,0
EPS (Diluted) 0,06 0,00 — — —
Gross Profit 3,24 M 1,31 M 484.407,0 — —
Operating Income 719.051,0 87.000,0 -251.500,0 -91.921,0 -25.610,0
EBITDA — — — — —
R&D Expenses 161.353,0 25.908,0 — — —
SG&A Expenses 2,21 M 1,15 M 706.257,0 91.921,0 25.610,0
D&A — — — — —
Interest Expense — — — 450,0 450,0
Income Tax 76.961,0 0,0 0,0 0,0 0,0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 1,71 M 873.788,0 93.388,0 16.253,0 6.314,0
Total Liabilities 229.851,0 38.548,0 100.148,0 1.860,0 19.106,0
Shareholders' Equity 1,48 M 835.240,0 -6.760,0 14.393,0 -12.792,0
Total Debt — — — — —
Cash & Equivalents 661.925,0 662.517,0 19.238,0 — 2.035,0
Current Assets 1,56 M 847.751,0 93.388,0 16.253,0 6.314,0
Current Liabilities — — — — —